Header Logo

HANA EL SAHLY

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Molecular Virology & Microbiology
AddressOne Baylor Plaza
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Medicine
    DivisionMedicine-Infectious Disease


    Collapse Research 
    Collapse research activities and funding
    UM1AI148575     (EL SAHLY, HANA M)Dec 11, 2019 - Nov 30, 2026
    NIH
    Vaccine and Treatment Evaluation Units (VTEU)
    Role: Principal Investigator
    R03AI074647     (EL SAHLI, HANA M)Sep 1, 2007 - Aug 31, 2010
    NIH
    Susceptibility of Mycobacterium tuberculosis clinical isolates to moxifloxacin
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rostad CA, Atmar RL, Walter EB, Frey S, Meier JL, Sherman AC, Lai L, Tsong R, Kao CM, Raabe V, El Sahly HM, Keitel WA, Whitaker JA, Smith MJ, Schmader KE, Swamy GK, Abate G, Winokur P, Buchanan W, Cross K, Wegel A, Xu Y, Yildirim I, Kamidani S, Rouphael N, Roberts PC, Mulligan MJ, Anderson EJ. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 Mar 27. PMID: 38537255.
      Citations:    Fields:    
    2. El Sahly HM, Yildirim I, Frey SE, Winokur P, Jackson LA, Bernstein DI, Creech CB, Chen WH, Rupp RE, Whitaker JA, Phadke V, Hoft DF, Ince D, Brady RC, Edwards KM, Ortiz JR, Berman MA, Weiss J, Wegel A, DMID 17-0090 Study Group , El Sahly HM, Yildirim I, Frey SE, Winokur P, Jackson LA, Bernstein DI, Creech CB, Chen WH, Rupp RE, Whitaker JA, Phadke V, Hoft DF, Ince D, Brady RC, Edwards KM, Ortiz JR, Berman MA, Weiss J, Wegel A. Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2024 Feb 14; 229(2):327-340. PMID: 37466221; PMCID: PMC10873179.
      Citations:    Fields:    Translation:HumansCells
    3. Ciocca ET, Staggers KA, Carey J, Opekun AR, Hollinger FB, Keitel WA, Atmar RL, El Sahly HM, Whitaker JA. Delays in Hepatitis A vaccination in people with HIV in Houston, Texas between 2010 and 2018. Vaccine X. 2024 Jan; 16:100422. PMID: 38192618; PMCID: PMC10772366.
      Citations:    
    4. Sheikh D, Staggers KA, Carey J, Keitel WA, Atmar RL, El Sahly HM, Whitaker JA. Delays in Hepatitis B Immunization Series Completion in People With Human Immunodeficiency Virus. Open Forum Infect Dis. 2023 Nov; 10(11):ofad543. PMID: 38033987; PMCID: PMC10686353.
      Citations: 1     
    5. Hejazi NS, Shen X, Carpp LN, Benkeser D, Follmann D, Janes HE, Baden LR, El Sahly HM, Deng W, Zhou H, Leav B, Montefiori DC, Gilbert PB. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. Int J Infect Dis. 2023 Dec; 137:28-39. PMID: 37820782; PMCID: PMC10841741.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    6. Huang Y, Hejazi NS, Blette B, Carpp LN, Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Kenny A, Carone M, Huynh C, Miller J, El Sahly HM, Baden LR, Jackson LA, Campbell TB, Clark J, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial. Viruses. 2023 09 29; 15(10). PMID: 37896806; PMCID: PMC10612023.
      Citations: 2     Fields:    Translation:Humans
    7. Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad CA, Maboa RM, Baden LR, El Sahly HM, Grinsztejn B, Gray GE, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Goepfert PA, Walsh SR, Follmann D, Kotloff KL, NIAID-funded COVID-19 Prevention Network (CoVPN). Risk of COVID-19 after natural infection or vaccination. EBioMedicine. 2023 Oct; 96:104799. PMID: 37738833; PMCID: PMC10518569.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    8. Eickhoff CS, Meza KA, Terry FE, Colbert CG, Blazevic A, Guti?rrez AH, Stone ET, Brien JD, Pinto AK, El Sahly HM, Mulligan MJ, Rouphael N, Alcaide ML, Tomashek KM, Focht C, Martin WD, Moise L, De Groot AS, Hoft DF. Identification of immunodominant T cell epitopes induced by natural Zika virus infection. Front Immunol. 2023; 14:1247876. PMID: 37705976; PMCID: PMC10497216.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    9. Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, B?cker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Kamidani S, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, Neuzil KM, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, T?reli S, Makhene M, Crandon S, Montefiori DC, Makowski M, Smith DJ, Nayak SU, Roberts PC, Beigel JH, COVAIL Study Group. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023 09; 29(9):2334-2346. PMID: 37640860; PMCID: PMC10504073.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    10. Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, B?cker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW, Rajakumar K, Kotloff K, Rouphael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryannyy L, Beigel JH, Montefiori DC, Roberts PC, DMID 21-0012 Study Group. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. NPJ Vaccines. 2023 Jul 11; 8(1):98. PMID: 37433788; PMCID: PMC10336079.
      Citations: 6     
    11. Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, Neuzil KM, Corey L, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, COVID-19 Prevention Network (CoVPN). Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 Jul 03; 6(7):e2323349. PMID: 37440227; PMCID: PMC10346130.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    12. Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Rouphael N, Luedtke A, COVID-19 Prevention Network CoVPN. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials. Vaccine. 2023 07 25; 41(33):4899-4906. PMID: 37385888; PMCID: PMC10288314.
      Citations:    Fields:    Translation:Humans
    13. Olson D, Lamb MM, Connery AK, Colbert AM, Calvimontes DM, Bauer D, Paniagua-Avila MA, Mart?nez MA, Arroyave P, Hernandez S, Colborn KL, Roell Y, Waggoner JJ, Natrajan MS, Anderson EJ, Bola?os GA, Munoz FM, Asturias EJ, El Sahly HM. Cumulative Febrile, Respiratory, and Gastrointestinal Illness Among Infants in Rural Guatemala and Association With Neurodevelopmental and Growth Outcomes. Pediatr Infect Dis J. 2023 09 01; 42(9):739-744. PMID: 37343218; PMCID: PMC10527407.
      Citations:    Fields:    Translation:Humans
    14. Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun. 2023 06 17; 14(1):3605. PMID: 37330602; PMCID: PMC10276829.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    15. Diaz C, El Sahly HM, Anderson EJ, Acosta CJ, Nordio F, Han HH, Moss KJ, Bohning K, Kumar P, Liu M, Patel H, Pacciarini F, Mwangi V, Walter E, Powell TD, Baldwin WR, Santangelo J, Dubin G. Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection. J Infect Dis. 2023 05 29; 227(11):1303-1312. PMID: 36484441; PMCID: PMC10226659.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    16. Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, El Sahly HM, Jain MK, Mehta AK, Wolfe CR, Gomez CA, Beresnev T, Mularski RA, Paules CI, Kalil AC, Branche AR, Luetkemeyer A, Zingman BS, Voell J, Whitaker M, Harkins MS, Davey RT, Grossberg R, George SL, Tapson V, Short WR, Ghazaryan V, Benson CA, Dodd LE, Sweeney DA, Tomashek KM. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case. Open Forum Infect Dis. 2023 Jun; 10(6):ofad290. PMID: 37383244; PMCID: PMC10296069.
      Citations:    
    17. Anderson E, Fusco D, Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Walter E, Novak R, Rupp R, Jackson L, Babu T, Kottkamp A, Luetkemeyer A, Immergluck L, Presti R, Backer M, Winokur P, Mahgoub S, Goepfert P, Malkin E, Bethony J, Walsh E, Graciaa D, Samaha H, Sherman A, Walsh S, Abate G, Oikonomopoulou Z, El Sahly H, Martin T, Kamidani S, Smith M, Ladner B, Porterfield L, Dunstan M, Wald A, Davis T, Atmar R, Mulligan M, Lyke K, Posavad C, Meagher M, Stephens D, Neuzil K, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis T, Giebeig L, Eaton A, Netzl A, Wilks S, Tureli S, Makhene M, Crandon S, Montefiori D, Makowski M, Smith D, Nayak S, Roberts P, Beigel J. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. Res Sq. 2023 May 05. PMID: 37205592; PMCID: PMC10187423.
      Citations:    
    18. Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Williamson BD, Garver J, Altonen E, Rudge T, Huynh C, Miller J, El Sahly HM, Baden LR, Frey S, Malkin E, Spector SA, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB, Immune Assays, Moderna Inc., Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE), United States Government (USG)/CoVPN Biostatistics Teams. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci Transl Med. 2023 04 19; 15(692):eade9078. PMID: 37075127; PMCID: PMC10243212.
      Citations: 4     Fields:    Translation:Humans
    19. Diemert DJ, Correa-Oliveira R, Fraga CG, Talles F, Silva MR, Patel SM, Galbiati S, Kennedy JK, Lundeen JS, Gazzinelli MF, Li G, Hoeweler L, Deye GA, Bottazzi ME, Hotez PJ, El Sahly HM, Keitel WA, Bethony J, Atmar RL. A randomized, controlled Phase 1b trial of the Sm-TSP-2 Vaccine for intestinal schistosomiasis in healthy Brazilian adults living in an endemic area. PLoS Negl Trop Dis. 2023 03; 17(3):e0011236. PMID: 36996185; PMCID: PMC10089325.
      Citations: 1     Fields:    Translation:HumansAnimalsCTClinical Trials
    20. Atmar RL, Bernstein DI, Winokur P, Frey SE, Angelo LS, Bryant C, Ben-Yedidia T, Roberts PC, El Sahly HM, Keitel WA. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722. PMID: 36941155; PMCID: PMC10396309.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    21. Follmann D, Janes HE, Chu E, Jayashankar L, Petropoulos CJ, Serebryannyy L, Carroll R, Jean-Baptiste N, Narpala S, Lin BC, McDermott A, Novak RM, Graciaa DS, Rolsma S, Magaret CA, Doria-Rose N, Corey L, Neuzil KM, Pajon R, Miller JM, Donis RO, Koup RA, Baden LR, El Sahly HM. Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. Open Forum Infect Dis. 2023 Mar; 10(3):ofad069. PMID: 36895286; PMCID: PMC9991588.
      Citations: 2     
    22. Siangphoe U, Baden LR, El Sahly HM, Essink B, Ali K, Berman G, Tomassini JE, Deng W, Pajon R, McPhee R, Dixit A, Das R, Miller JM, Zhou H, COVE and TeenCOVE Study Groups. Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clin Infect Dis. 2023 01 13; 76(2):271-280. PMID: 36130187; PMCID: PMC10202429.
      Citations:    
    23. Neuzil KM, Anderson EJ, Frenck RW, Frey SE, Walter EB, Rupp R, Rotrosen ET, Rouphael NG, Brady RC, Graham I, Schmader KE, Porterfield L, Ortiz JR, Swamy GK, El Sahly HM, Jeevan T, Sitaula R, Wegel A, Webby RJ, Bryant C, Influenza A/H5N8 Virus Vaccine Group . Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses. Clin Infect Dis. 2023 Jan 05. PMID: 36610728.
      Citations: 1     Fields:    
    24. Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG, COVID-19 Prevention Network. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 01 03; 6(1):e2251974. PMID: 36689221; PMCID: PMC10546713.
      Citations: 4     Fields:    Translation:HumansCellsPHPublic Health
    25. Tsalik EL, Rouphael NG, Sadikot RT, Rodriguez-Barradas MC, McClain MT, Wilkins DM, Woods CW, Swamy GK, Walter EB, El Sahly HM, Keitel WA, Mulligan MJ, Tuyishimire B, Serti E, Hamasaki T, Evans SR, Ghazaryan V, Lee MS, Lautenbach E, TRAP-LRTI Study Group, Antibacterial Resistance Leadership Group. Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial. Lancet Infect Dis. 2023 04; 23(4):484-495. PMID: 36525985; PMCID: PMC10040424.
      Citations: 2     Fields:    Translation:Humans
    26. Paniagua-Avila A, Olson D, Connery A, Calvimontes DM, Bolanos GA, Lamb MM, Bauer D, Ralda A, Rojop N, Barrios E, Chacon A, Gomez M, Arroyave P, Hernandez S, Martinez MA, Bunge-Montes S, Colbert A, Arias K, Brazeale G, Holliday A, Tomashek KM, El Sahly HM, Keitel W, Munoz FM, Asturias EJ. Challenges and lessons learned from the rapid operationalization of a prospective cohort to study the natural history and neurodevelopmental outcomes of postnatal Zika virus infection among infants and children in rural Guatemala. PLoS Negl Trop Dis. 2022 11; 16(11):e0010480. PMID: 36383617; PMCID: PMC9710790.
      Citations: 1     Fields:    Translation:HumansCells
    27. El Sahly HM, Baden LR, Essink B, Montefiori D, McDermont A, Rupp R, Lewis M, Swaminathan S, Griffin C, Fragoso V, Miller VE, Girard B, Paila YD, Deng W, Tomassini JE, Paris R, Das R, August A, Leav B, Miller JM, Zhou H, Pajon R, Coronavirus Efficacy (COVE) Study Group, Sch?del F. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. J Infect Dis. 2022 11 11; 226(10):1731-1742. PMID: 35535503; PMCID: PMC9213865.
      Citations:    Fields:    
    28. Wang G, Stapleton JT, Baker AW, Rouphael N, Creech CB, El Sahly HM, Stout JE, Jackson L, Charbek E, Leyva FJ, Tomashek KM, Tibbals M, Miller A, Frey S, Niemotka S, Wiemken TL, Beydoun N, Alaaeddine G, Turner N, Walter EB, Chamberland R, Abate G. Clinical Features and Treatment Outcomes of Pulmonary Mycobacterium avium-intracellulare Complex With and Without Coinfections. Open Forum Infect Dis. 2022 Aug; 9(8):ofac375. PMID: 35959208; PMCID: PMC9361173.
      Citations:    
    29. Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Rostad CA, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, Neuzil KM, Abebe K, Hill H, Albert J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Makhene M, Crandon S, Lee M, Nayak SU, Montefiori DC, Makowski M, Smith DJ, Roberts PC, Beigel JH, COVAIL Study Group, B?cker M, T?reli S. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. medRxiv. 2022 Jul 15. PMID: 35898343; PMCID: PMC9327623.
      Citations:    
    30. Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR, Desjardins M. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med. 2022 09; 175(9):1258-1265. PMID: 35785530; PMCID: PMC9258784.
      Citations:    Fields:    
    31. Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, Deming ME, Eaton A, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Archer JI, Crandon S, Zemanek JA, Brown ER, Neuzil KM, Stephens DS, Post DJ, Nayak SU, Suthar MS, Roberts PC, Beigel JH, Montefiori DC, DMID 21-0012 Study Group, B?cker M. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 07 19; 3(7):100679. PMID: 35798000; PMCID: PMC9212999.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    32. Lin DY, Baden LR, El Sahly HM, Essink B, Neuzil KM, Corey L, Miller J, COVE Study Group. Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. JAMA Netw Open. 2022 06 01; 5(6):e2215984. PMID: 35675078; PMCID: PMC9178430.
      Citations:    Fields:    Translation:Humans
    33. Wolfe CR, Tomashek KM, Patterson TF, Gomez CA, Marconi VC, Jain MK, Yang OO, Paules CI, Grossberg R, Harkins MS, Mularski RA, Erdmann N, Sandkovsky U, Almasri E, Pineda JR, Dretler AW, de Castilla DL, Branche AR, Park PK, Mehta AK, Short WR, McLellan SLF, Kline S, Iovine NM, El Sahly HM, Doernberg SB, Oh MD, Huprikar N, Hohmann E, Kelley CF, Holodniy M, Kim ES, Sweeney DA, Finberg RW, Grimes KA, Maves RC, Ko ER, Engemann JJ, Taylor BS, Ponce PO, Larson L, Melendez DP, Seibert AM, Rouphael NG, Strebe J, Clark JL, Julian KG, Cardoso A, de Bono S, Atmar RL, Ganesan A, Ferreira JL, Green M, Makowski M, Bonnett T, Beresnev T, Ghazaryan V, Dempsey W, Nayak SU, Dodd LE, Beigel JH, Kalil AC, ACTT-4 Study Group, Palacios GMR, de Leon AP. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022 09; 10(9):888-899. PMID: 35617986; PMCID: PMC9126560.
      Citations: 2     Fields:    
    34. Fintzi J, Bonnett T, Tebas P, Marconi VC, Levine CB, El Sahly HM, McLellan SLF, Benson CA, Rostad CA, Ganesan A, Huprikar N, Frank MG, Mularski RA, Atmar RL, Park PK, Short WR, Beigel JH, Mehta AK, Sweeney DA. Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infect Dis. 2022 Jul; 9(7):ofac219. PMID: 35818363; PMCID: PMC9129131.
      Citations:    
    35. Pajon R, Paila YD, Girard B, Dixon G, Kacena K, Baden LR, El Sahly HM, Essink B, Mullane KM, Frank I, Denhan D, Kerwin E, Zhao X, Ding B, Deng W, Tomassini JE, Zhou H, Leav B, COVE Trial Consortium, Sch?del F. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat Med. 2022 04; 28(4):823-830. PMID: 35145311; PMCID: PMC9018421.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    36. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH, DMID 21-0012 Study Group, B?cker M. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057. PMID: 35081293; PMCID: PMC8820244.
      Citations: 71     Fields:    Translation:HumansCellsCTClinical Trials
    37. Pajon R, Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore KM, Floyd K, Foster SL, Posavad CM, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Sullivan NJ, Roberts PC, Beigel JH, Korber B, Baden LR, El Sahly H, Chalkias S, Zhou H, Feng J, Girard B, Das R, Aunins A, Edwards DK, Suthar MS, Mascola JR, Montefiori DC. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022 03 17; 386(11):1088-1091. PMID: 35081298; PMCID: PMC8809504.
      Citations: 69     Fields:    
    38. Akamine CM, El Sahly HM. Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review. Transl Res. 2022 04; 242:1-19. PMID: 34954088; PMCID: PMC8695521.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    39. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Immune Assays Team?, Moderna, Inc. Team?, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team?, United States Government (USG)/CoVPN Biostatistics Team?. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50. PMID: 34812653; PMCID: PMC9017870.
      Citations: 169     Fields:    Translation:HumansCells
    40. El Sahly HM, Atmar RL, Sendra E, Wegel A, Keitel WA. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719. PMID: 33852718; PMCID: PMC9633716.
      Citations: 1     Fields:    
    41. Baden LR, El Sahly HM, Essink B, Follmann D, Neuzil KM, August A, Clouting H, Fortier G, Deng W, Han S, Zhao X, Leav B, Talarico C, Girard B, Paila YD, Tomassini JE, Pajon R, Zhou H, Das R, Miller J, Sch?del F. Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. N Engl J Med. 2021 12 23; 385(26):2485-2487. PMID: 34731553; PMCID: PMC8609569.
      Citations: 19     Fields:    
    42. DMID 21-0012 Study Group, Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, B?cker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobryzynski D, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek J, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH. Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report. medRxiv. 2021 Oct 15. PMID: 34671773; PMCID: PMC8528081.
      Citations:    
    43. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Tomassini JE, Zhou H, Miller J, COVE Study Group, Sch?del F. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 04; 385(19):1774-1785. PMID: 34551225; PMCID: PMC8482810.
      Citations: 105     Fields:    Translation:HumansCTClinical Trials
    44. Baden LR, El Sahly HM, Essink B, Follmann D, Neuzil KM, August A, Clouting H, Fortier G, Deng W, Han S, Zhao X, Leav B, Talarico C, Girard B, Paila YD, Tomassini JE, Pajon R, Zhou H, Das R, Miller J, Sch?del F. Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge. medRxiv. 2021 Sep 22. PMID: 34611666; PMCID: PMC8491857.
      Citations: 1     
    45. Colbert AM, Connery AK, Lamb MM, Bauer D, Olson D, Paniagua-Avila A, Arroyave P, Mirella Calvimontes D, El Sahly HM, Asturias EJ, Mart?nez MA, Hern?ndez S, Bola?os GA, Mu?oz FM. Caregiver rating of early childhood development: Reliability and validity of the ASQ-3 in rural Guatemala. Early Hum Dev. 2021 10; 161:105453. PMID: 34530320.
      Citations:    Fields:    Translation:Humans
    46. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi N, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Kutner M, Andrasik MP, Kublin JG, Corey L, Neuzil KM, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA. Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv. 2021 Aug 15. PMID: 34401888; PMCID: PMC8366808.
      Citations:    
    47. Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, Neuzil KM. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Ann Intern Med. 2021 08; 174(8):1118-1125. PMID: 33844575; PMCID: PMC8099035.
      Citations: 8     Fields:    Translation:HumansCells
    48. Abate G, Stapleton JT, Rouphael N, Creech B, Stout JE, El Sahly HM, Jackson L, Leyva FJ, Tomashek KM, Tibbals M, Watson N, Miller A, Charbek E, Siegner J, Sokol-Anderson M, Nayak R, Dahlberg G, Winokur P, Alaaeddine G, Beydoun N, Sokolow K, Kown NP, Phillips S, Baker AW, Turner N, Walter E, Guy E, Frey S. Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. Clin Infect Dis. 2021 04 08; 72(7):1127-1137. PMID: 32198521; PMCID: PMC8028102.
      Citations: 3     Fields:    Translation:HumansCells
    49. Waggoner JJ, Stittleburg V, Natrajan MS, Bauer D, Olson D, El Sahly HM, Asturias EJ, Anderson EJ, Munoz FM, Paniagua-Avila A. Sensitive and Prolonged Detection of Dengue Virus RNA in Whole Blood. Am J Trop Med Hyg. 2021 03 22; 104(5):1734-1736. PMID: 33755591; PMCID: PMC8103463.
      Citations: 1     Fields:    Translation:HumansCells
    50. Connery AK, Lamb MM, Colbert AM, El Sahly HM, Olson D, Asturias EJ, Munoz FM, Bauer D, Hern?ndez S, Arroyave P, Mart?nez MA, Barrios EE, Paniagua-Avila A, Calvimontes M, Bola?os GA. Parent Report of Health Related Quality of Life in Young Children in Rural Guatemala: Implementation, Reliability, and Validity of the PedsQL in Stunting and Wasting. Glob Pediatr Health. 2021; 8:2333794X21991028. PMID: 33614851; PMCID: PMC7868501.
      Citations:    
    51. Winokur P, El Sahly HM, Mulligan MJ, Frey SE, Rupp R, Anderson EJ, Edwards KM, Bernstein DI, Schmader K, Jackson LA, Chen WH, Hill H, Bellamy A, DMID 13-0034 H7N9 Vaccine Study Group. Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65?years and older. Vaccine. 2021 02 22; 39(8):1339-1348. PMID: 33485646; PMCID: PMC8504682.
      Citations:    Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    52. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 02 04; 384(5):403-416. PMID: 33378609; PMCID: PMC7787219.
      Citations: 2665     Fields:    Translation:HumansCellsCTClinical Trials
    53. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Rouphael NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH, ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 03 04; 384(9):795-807. PMID: 33306283; PMCID: PMC7745180.
      Citations: 510     Fields:    Translation:Humans
    54. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: An Overview and Approach to Classification. Open Forum Infect Dis. 2020 Dec; 7(12):ofaa509. PMID: 33403218; PMCID: PMC7665635.
      Citations: 37     
    55. Harrison D, Muradali K, El Sahly H, Bozkurt B, Jneid H. Impact of the SARS-CoV-2 pandemic on health-care workers. Hosp Pract (1995). 2020 Oct; 48(4):161-164. PMID: 32520629.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic Health
    56. El Sahly HM, Makedonas G, Corry D, Atmar RL, Bellamy A, Cross K, Keitel WA. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145. PMID: 32401699; PMCID: PMC8641601.
      Citations: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    57. Colbert AM, Lamb MM, Asturias EJ, Olson D, El Sahly HM, Connery AK, Mu?oz FM, Bauer D, Arroyave P, Hern?ndez S, Mart?nez MA, Paniagua-Avila A, Calvimontes DM, Bola?os GA. Reliability and Validity of an Adapted and Translated Version of the Mullen Scales of Early Learning (AT-MSEL) in Rural Guatemala. Child Care Health Dev. 2020 05; 46(3):327-335. PMID: 31978249.
      Citations: 1     Fields:    Translation:Humans
    58. Cheema A, Mathias K, Bui C, Dunham SR, Clay Goodman J, El Sahly HM. CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV - ERRATUM. Can J Neurol Sci. 2020 Jan; 47(1):151. PMID: 31796133.
      Citations:    Fields:    
    59. Cheema A, Mathias K, Bui C, Dunham SR, Goodman JC, El Sahly HM. CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV. Can J Neurol Sci. 2019 11; 46(6):773-775. PMID: 31466541.
      Citations: 2     Fields:    Translation:HumansCells
    60. Lichtenberger PN, Ricciardi MJ, Solorzano D, Raccamarich P, Leda A, Sharkey M, Watkins DI, El Sahly H, Rouphael N, Mulligan MJ, Doblecki-Lewis S, Stevenson M, Alcaide ML. Occupational Exposure to the Ugandan Research Strain (MR766) of Zika Virus. Open Forum Infect Dis. 2019 Oct; 6(10):ofz420. PMID: 31667199; PMCID: PMC6814281.
      Citations: 1     
    61. Keitel WA, Potter GE, Diemert D, Bethony J, El Sahly HM, Kennedy JK, Patel SM, Plieskatt JL, Jones W, Deye G, Bottazzi ME, Hotez PJ, Atmar RL. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509. PMID: 31515141; PMCID: PMC6771426.
      Citations: 16     Fields:    Translation:HumansAnimalsCTClinical Trials
    62. Connery AK, Colbert AM, Lamb MM, El Sahly HM, Olson D, Asturias EJ, Munoz FM, Hern?ndez S, Mart?nez MA, Bauer D, Arroyave P, Paniagua-Avila A, Calvimontes M, Bola?os GA. Receptive language skills among young children in rural Guatemala: The relationship between the Test de Vocabulario en Imagenes Peabody and a translated and adapted version of the Mullen Scales of Early Learning. Child Care Health Dev. 2019 09; 45(5):702-708. PMID: 31270836.
      Citations: 2     Fields:    Translation:Humans
    63. Manwani B, Xu Y, El Sahly HM. Hepatic abscesses due to Clostridium septicum infection and its association with colonic adenocarcinoma: a case report and literature review. Clin J Gastroenterol. 2020 Feb; 13(1):66-72. PMID: 31190186.
      Citations:    Fields:    Translation:HumansCells
    64. El Chaer F, El Sahly HM. The Reply. Am J Med. 2019 08; 132(8):e668. PMID: 31153868.
      Citations:    Fields:    Translation:HumansPHPublic Health
    65. El Sahly HM, Atmar RL, Patel SM, Bellamy A, Liu L, Hong W, Zhu H, Guan Y, Keitel WA, DMID 13-0033 Vaccine Study Group. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568. PMID: 30955980; PMCID: PMC6519114.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    66. Gorchakov R, Berry RM, Patel SM, El Sahly HM, Ronca SE, Murray KO. Optimizing PCR Detection of Zika Virus from Various Body Fluids. Am J Trop Med Hyg. 2019 02; 100(2):427-433. PMID: 30560770; PMCID: PMC6367632.
      Citations: 9     Fields:    Translation:HumansCells
    67. El Chaer F, El Sahly HM. Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. Am J Med. 2019 04; 132(4):437-446. PMID: 30611828.
      Citations: 10     Fields:    Translation:Humans
    68. El Sahly HM, Gorchakov R, Lai L, Natrajan MS, Patel SM, Atmar RL, Keitel WA, Hoft DF, Barrett J, Bailey J, Edupuganti S, Raabe V, Wu HM, Fairley J, Rouphael N, Murray KO, Mulligan MJ. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. Open Forum Infect Dis. 2019 Jan; 6(1):ofy352. PMID: 30697574; PMCID: PMC6343961.
      Citations: 15     
    69. Jackson LA, El Sahly HM, George S, Winokur P, Edwards K, Brady RC, Rouphael N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74?years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2018 01 29; 36(5):606-614. PMID: 29279281; PMCID: PMC5777223.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    70. Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, Pasetti MF, Sztein MB, Hill H, Goll JB, DMID 08-0006 Tularemia Vaccine Study Group. Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial. Vaccine. 2017 08 24; 35(36):4730-4737. PMID: 28750854; PMCID: PMC5800773.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    71. El Sahly H, Udayamurthy M, Parkerson G, Hasbun R. Survival of an AIDS patient after infection with Acanthamoeba sp. of the central nervous system. Infection. 2017 Oct; 45(5):715-718. PMID: 28639141.
      Citations: 6     Fields:    Translation:HumansAnimals
    72. Kohli A, Weatherhead J, El Sahly H, Cort?s-Penfield N. Arcanobacterium haemolyticum CNS abscess and bacteremia following head trauma: a case report and literature review. Infect Dis Clin Pract (Baltim Md). 2017 May; 25(3):e9-e11. PMID: 30906173; PMCID: PMC6430583.
      Citations: 1     
    73. Jackson LA, Frey SE, El Sahly HM, Mulligan MJ, Winokur PL, Kotloff KL, Campbell JD, Atmar RL, Graham I, Anderson EJ, Anderson EL, Patel SM, Fields C, Keitel W, Rouphael N, Hill H, Goll JB. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682. PMID: 28256358.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    74. Treanor JJ, Chu L, Essink B, Muse D, El Sahly HM, Izikson R, Goldenthal KL, Patriarca P, Dunkle LM. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 2017 02 07; 35(6):923-928. PMID: 28089141.
      Citations: 4     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    75. Quinn CP, Sabourin CL, Schiffer JM, Niemuth NA, Semenova VA, Li H, Rudge TL, Brys AM, Mittler RS, Ibegbu CC, Wrammert J, Ahmed R, Parker SD, Babcock J, Keitel W, Poland GA, Keyserling HL, El Sahly H, Jacobson RM, Marano N, Plikaytis BD, Wright JG. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. Clin Vaccine Immunol. 2016 Apr; 23(4):326-38. PMID: 26865594; PMCID: PMC4820509.
      Citations: 3     Fields:    Translation:HumansCells
    76. Barrows BD, Stager CE, Finch CJ, El Sahly HM, Weatherhead JE. Gastrointestinal Coccidioidomycosis. J Clin Gastroenterol. 2015 Aug; 49(7):628-9. PMID: 25887112.
      Citations: 2     Fields:    Translation:Humans
    77. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46. PMID: 26197184.
      Citations: 62     Fields:    Translation:HumansCellsCTClinical Trials
    78. Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, El Sahly H, El-Kamary SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Anderson EL, Graham IL, Johnston C, Mulligan M, Rouphael N, Atmar R, Patel S, Chen W, Kotloff K, Creech CB, Chaplin P, Belshe RB. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34. PMID: 26143613; PMCID: PMC9533873.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    79. El Chaer F, Harris N, El Sahly H, Hemmige V, Martinez Blanco E, Woc-Colburn L. Mycobacterium avium complex-associated cholecystitis in AIDS patient: a case description and review of literature. Int J STD AIDS. 2016 11; 27(13):1218-1222. PMID: 26023092.
      Citations: 1     Fields:    Translation:HumansCells
    80. Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73. PMID: 25444805; PMCID: PMC4293632.
      Citations: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    81. Bernstein DI, Jackson L, Patel SM, El Sahly HM, Spearman P, Rouphael N, Rudge TL, Hill H, Goll JB. Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine. 2014 Oct 29; 32(47):6284-93. PMID: 25239484; PMCID: PMC4250293.
      Citations: 6     Fields:    Translation:Humans
    82. El Sahly HM. Performance of Xpert MTB/RIF in induced sputum samples at detecting Mycobacterium tuberculosis. Clin Infect Dis. 2014 Sep 15; 59(6):911-2. PMID: 24855147.
      Citations:    Fields:    Translation:Humans
    83. Wright JG, Plikaytis BD, Rose CE, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semenova VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial. Vaccine. 2014 Feb 12; 32(8):1019-28. PMID: 24373307; PMCID: PMC9067390.
      Citations: 21     Fields:    Translation:Humans
    84. El Sahly HM, Teeter LD, Musser JM, Graviss EA. Mycobacterium tuberculosis bacteraemia: experience from a non-endemic urban centre. Clin Microbiol Infect. 2014 Mar; 20(3):263-8. PMID: 23980760; PMCID: PMC4004024.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    85. Keitel WA, Piedra PA, Atmar RL, Demmler G, El Sahly HM, Barrett J, Halpin RA, Lagos R, Fisher-Hoch S, Munoz F. Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised). BMC Res Notes. 2013 May 03; 6:177. PMID: 23641940; PMCID: PMC3651415.
      Citations:    Fields:    Translation:HumansCells
    86. Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77. PMID: 22891287; PMCID: PMC3501693.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    87. El Sahly HM, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, Johnston C, George SL, Brady RC, Lehmann C, Stokes-Riner A, Keitel WA. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012 Mar 01; 205(5):703-12. PMID: 22275399; PMCID: PMC3274370.
      Citations: 14     Fields:    Translation:HumansCells
    88. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13; 29(44):7733-9. PMID: 21835220.
      Citations: 67     Fields:    Translation:HumansCellsPHPublic Health
    89. Bernstein DI, El Sahly HM, Keitel WA, Wolff M, Simone G, Segawa C, Wong S, Shelly D, Young NS, Dempsey W. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63. PMID: 21807052; PMCID: PMC3186820.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    90. El Sahly HM, Teeter LD, Jost KC, Dunbar D, Lew J, Graviss EA. Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. J Clin Microbiol. 2011 Aug; 49(8):2942-5. PMID: 21653760; PMCID: PMC3147712.
      Citations: 5     Fields:    Translation:HumansCells
    91. El Sahly H. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010 Oct; 9(10):1135-41. PMID: 20923265.
      Citations: 28     Fields:    Translation:HumansCells
    92. El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Sim BK, Long C, Keitel WA. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic. Clin Vaccine Immunol. 2010 Oct; 17(10):1552-9. PMID: 20702657; PMCID: PMC2952998.
      Citations: 31     Fields:    Translation:HumansAnimalsPHPublic Health
    93. Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9. PMID: 19931380; PMCID: PMC2913582.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    94. Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine. 2009 Dec 11; 28(2):379-85. PMID: 19879222.
      Citations: 14     Fields:    Translation:Humans
    95. Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V, Selinsky C, Kaslow DC, Rolland A, Smith LR, Lalor PA. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin. 2009 Aug; 5(8):536-44. PMID: 19458488; PMCID: PMC3041018.
      Citations: 6     Fields:    Translation:HumansAnimalsCellsPHPublic HealthCTClinical Trials
    96. El Sahly HM, Atmar RL, Patel SM, Wells JM, Cate T, Ho M, Guo K, Pasetti MF, Lewis DE, Sztein MB, Keitel WA. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine. 2009 Aug 06; 27(36):4905-11. PMID: 19567246; PMCID: PMC2726995.
      Citations: 29     Fields:    Translation:HumansCells
    97. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP, Anthrax Vaccine Research Program Working Group. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA. 2008 Oct 01; 300(13):1532-43. PMID: 18827210.
      Citations: 46     Fields:    Translation:HumansCellsCTClinical Trials
    98. El Sahly HM, Keitel WA. Clinical data on Fluarix: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines. 2008 Aug; 7(6):713-9. PMID: 18665769.
      Citations: 4     Fields:    Translation:HumansCells
    99. El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines. 2008 Mar; 7(2):241-7. PMID: 18324892.
      Citations: 18     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    100. El Sahly HM, Teeter LD, Pan X, Musser JM, Graviss EA. Mortality associated with central nervous system tuberculosis. J Infect. 2007 Dec; 55(6):502-9. PMID: 17920686; PMCID: PMC2174908.
      Citations: 14     Fields:    Translation:HumansPHPublic Health
    101. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 01; 43(9):1135-42. PMID: 17029131.
      Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
    102. El Sahly HM, Teeter L, Zerai T, Andrade RA, Munoz C, Nnabuife C, Hunter R. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. AIDS. 2006 Mar 21; 20(5):786-7. PMID: 16514316.
      Citations: 3     Fields:    Translation:Humans
    103. El Sahly HM, Teeter LD, Pawlak RR, Musser JM, Graviss EA. Drug-resistant tuberculosis: a disease of target populations in Houston, Texas. J Infect. 2006 Jul; 53(1):5-11. PMID: 16310855.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    104. El Sahly HM, Wright JA, Soini H, Bui TT, Williams-Bouyer N, Escalante P, Musser JM, Graviss EA. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis. 2004 Mar; 8(3):333-40. PMID: 15139472.
      Citations: 13     Fields:    Translation:HumansCellsPHPublic Health
    105. El Sahly HM, Reich RA, Dou SJ, Musser JM, Graviss EA. The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. Scand J Infect Dis. 2004; 36(2):106-8. PMID: 15061663.
      Citations: 15     Fields:    Translation:Humans
    106. El Sahly HM, Septimus E, Soini H, Septimus J, Wallace RJ, Pan X, Williams-Bouyer N, Musser JM, Graviss EA. Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin Infect Dis. 2002 Oct 01; 35(7):802-7. PMID: 12228816.
      Citations: 21     Fields:    Translation:HumansCellsPHPublic Health
    107. Ma X, Dou S, Wright JA, Reich RA, Teeter LD, El Sahly HM, Awe RJ, Musser JM, Graviss EA. 5' dinucleotide repeat polymorphism of NRAMP1 and susceptibility to tuberculosis among Caucasian patients in Houston, Texas. Int J Tuberc Lung Dis. 2002 Sep; 6(9):818-23. PMID: 12234138.
      Citations: 18     Fields:    Translation:HumansCells
    108. El Sahly HM, Adams GJ, Soini H, Teeter L, Musser JM, Graviss EA. Epidemiologic differences between United States- and foreign-born tuberculosis patients in Houston, Texas. J Infect Dis. 2001 Feb 01; 183(3):461-8. PMID: 11133378.
      Citations: 16     Fields:    Translation:HumansCellsPHPublic Health
    109. Ramaswamy SV, Amin AG, Stager CE, Dou SJ, El Sahly H, Moghazeh SL, Kreiswirth BN, Musser JM, G?ksel S. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000 Feb; 44(2):326-36. PMID: 10639358; PMCID: PMC89679.
      Citations: 85     Fields:    Translation:HumansCells
    EL SAHLY's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (325)
    Explore
    _
    Co-Authors (28)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _